A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

University of Michigan and Centers for Disease Control and Prevention (CDC) investigators determined that both maternal ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

The following is a summary of “RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing,” published in the ...

Respiratory syncytial virus (RSV) is an infectious respiratory disease that can look and sound a lot like a cold, with ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness, according to two studies published online Nov. 25 in Pediatrics.

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

The good news: In October, a new preventive medicine, the monoclonal antibody Nirsevimab, became available to babies and at-risk toddlers to help protect them from RSV (Respiratory Syncytial Virus).

In most parts of the U.S., the RSV season lasts from October through March and peaks in December or January. Nirsevimab immunization is for infants under 8 months of age during RSV season.